Schizophrenia Treatment Market By Disease Symptoms 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Schizophrenia Treatment Market
Schizophrenia Treatment Market: By Disease Symptoms (Changes in Thought, Emotions, Behavior), By Remedies (Individual Therapy, Social Skills Training, Family Therapy, Vocational Rehabilitation & Supported Employment, Others) & By Geography-Forecast (2016-2021)
Report Code : HCR 0273
Published: 28 June, 2016   No. of pages: 150

  • Report Description
  • Table of Contents
  • Customization Options
Schizophrenia is a disease which disrupts an individual thought, emotions, behavior and even perceptions. The disease, begins at late teens or early adulthood (around twenties), disrupts functioning of a brain. Medically, Schizophrenia is characterized by a bunch of diseases and its symptoms could be overlapping. Treatments are done at both medical and psychosocial level while in severe cases hospitalization is also required. While early intervention programs will definitely reduce the risk of Schizophrenia, it is said that a lifelong treatment is required even when the symptoms subsidizes.

Efforts by a psychologist, social worker, psychiatric nurse and a case manager to coordinate care have proved to be beneficial for treating Schizophrenia. In addition, medications including antidepressants or anti-anxiety drugs are also helpful. However, it is argued that there is a higher level of risk of side effects with antipsychotic medications which are required to cure signs and symptoms with minimal dosage. The consequence may result in the possibility of developing a movement disorder (tardive dyskinesia) that may or may not be reversible. As a result, patients are reluctant to take such medications.

To overcome this, researchers have developed a new generation of medications which they claim lowers the risk of side effects. The Schizophrenia disorder treatment market is classified on the basis of following remedies: Individual therapy, Social skills training, Family therapy and Vocational rehabilitation and supported employment.

The Unites States is the largest market in terms of sales for Schizophrenia in 2016, followed by Japan and the European Union (EU). Major drug manufacturers have clustered around North America, particularly in the United States, thereby driving sales in this region. The total sales of drugs for Schizophrenia are expected to rise supported by the fact that people are getting more familiar with this disease and are taking precautions at an early stage. 

Schizophrenia Treatment Market

The Schizophrenia market report has been analyzed and segmented into the following types based on various factors like:

  • By Type: Schizophrenia Disorder, Asperger Syndrome, Pervasive Developmental Disorder, Others
  • By Market Approach: Behavioral Approaches, Early Intervention, Medication, Dietary Approach, Others
  • By Remedies: Individual Remedies, Social Skills Training, Family Therapy, Others
  • By Geography: This report has been further segmented into major regions which includes detailed analysis of each region such as: North America (United States, Canada and Mexico), Europe (Germany, U.K., France, Italy, Spain and Russia), Asia-Pacific (India, China, South Korea and Japan), and Rest of the World (RoW) covering all the major country level markets in each of the region.

Some of the key players treating Schizophrenia disorder are:

  • Minerva Neurosciences (US)
  • PROMENTIS (US)
  • Bristol-Myers Squibb Company (US)
  • PsychoGenics
  • AVINEURO PHARMACEUTICALS
1. Schizophrenia Treatment Market Overview
2. Executive Summary
3. Schizophrenia Treatment market landscape

   3.1. Product Benchmarking
   3.2. End user benchmarking
   3.3. Top 5 financial analysis
4. Schizophrenia Treatment– Market Forces
   4.1. Market Drivers
   4.2. Market Constraints
   4.3. Market Challenges
   4.4. Attractiveness of the Industry
      4.4.1. Bargaining Power of Suppliers
      4.4.2. Bragaining Power of Buyers
      4.4.3. Threat of New Entrants
      4.4.4. Threat of Substitutes
      4.4.5. Degree of Competition
5. Schizophrenia Treatment Market– Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Opprotunity Analysis
   5.3. Product/Market Life Cycle Analysis
6. Schizophrenia Treatment Market-By Type
   6.1. Schizophrenia Disorder
   6.2. Asperger Syndrome
   6.3. Pervasive Developmental Disorder
   6.4. Childhood Disintegrative Disorder
   6.5. Others
7. Schizophrenia Treatment Market-By Market Approach
   7.1. Behavioral Approaches
   7.2. Early Intervention
   7.3. Medication 
   7.4. Dietary Approach   
   7.5. Others 
8. Schizophrenia Treatment Market-By Remedies
   8.1. Individual remedies
   8.2. Social skills training
   8.3. Family therapy 
   8.4. Vocational rehabilitation and supported employment                
9. Schizophrenia Treatment Market-Geographic Analysis
   9.1. Americas
      9.1.1. Canada
      9.1.2. Mexico
      9.1.3. United States
   9.2. Europe
      9.2.1. UK
      9.2.2. France
      9.2.3. Germany
      9.2.4. France
      9.2.5. Italy
      9.2.6. Spain
      9.2.7. Russia
   9.3. Asia Pacific
      9.3.1. China
      9.3.2. South Korea
      9.3.3. Japan
      9.3.4. India
   9.4. Rest of the World (RoW)
10. Market Entropy
   10.1. New product launches
   10.2. Merger & Acquisitions, and Joint Ventures
   10.3. Supply- Contract
11. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
   11.1. Bristol-Myers Squibb Company (US)
   11.2. PROMENTIS
   11.3. Bristol-Myers Squibb Company
   11.4. PsychoGenics
   11.5. Avineuro Pharmaceuticals
   11.6. Novartis AG
   11.7. Merz Pharma
   11.8. Eli Lilly & Company
   11.9. Johnson & Johnson.
   11.10. Pfizer
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
12. Appendix

   12.1. Abbreviations
   12.2. Sources
   12.3. Research Methodology
   12.4. Bibliography
   12.5. Compilation of Expert Insights
   12.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports